Septerna (Nasdaq:SEPN) - Stock Price, News & Analysis

SEPN Stock Overview

A clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. More details

SEPN fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 69.29% per year

Revenue grew by 1019.1% over the past year

Analysts in good agreement that stock price will rise by 94.1%

Risk Analysis

Earnings are forecast to decline by an average of 64.6% per year for the next 3 years

Makes less than USD$1m in revenue ($838K)

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

Septerna, Inc. Competitors

Amryt Pharma

NasdaqGS:AMYT

US$940.7m

Nuvation Bio

NYSE:NUVB

US$871.7m

Collegium Pharmaceutical

NasdaqGS:COLL

US$959.4m

Phibro Animal Health

NasdaqGM:PAHC

US$962.0m

Price History & Performance

Summary of all time highs, changes and price drops for Septerna
Historical stock prices
Current Share Price	US$22.50
52 Week High	US$26.34
52 Week Low	US$18.62
Beta	0
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	5.14%

Recent updates

Shareholder Returns

	SEPN	US Pharmaceuticals	US Market
7D	-3.1%	-3.8%	-1.0%
1Y	n/a	9.8%	30.3%

Return vs Industry: Insufficient data to determine how SEPN performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how SEPN performed against the US Market.

Price Volatility

Is SEPN's price volatile compared to industry and market?
SEPN volatility
SEPN Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	9.6%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stable Share Price: SEPN's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine SEPN's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2019	68	Jeff Finer	septerna.com

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves’ disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes.

Septerna, Inc. Fundamentals Summary

How do Septerna's earnings and revenue compare to its market cap?
SEPN fundamental statistics
Market cap	US$1.02b
Earnings (TTM)	-US$10.27m
Revenue (TTM)	US$838.00k

1,128x

P/S Ratio

-92.0x

P/E Ratio

Is SEPN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SEPN income statement (TTM)
Revenue	US$838.00k
Cost of Revenue	US$0
Gross Profit	US$838.00k
Other Expenses	US$11.11m
Earnings	-US$10.27m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.24
Gross Margin	100.00%
Net Profit Margin	-1,225.66%
Debt/Equity Ratio	0%

How did SEPN perform over the long term?

See historical performance and comparison

Septerna NasdaqGM:SEPN Stock Report